Fortress Biotech (FBIOP) Stock Price, News & Analysis

Company Overview

Fortress Biotech, Inc. is a biopharmaceutical company engaged in the acquisition, development and commercialization of pharmaceutical and biotechnology products. Headquartered in New York, the company advances a diverse portfolio of drug candidates through a network of wholly owned and partnered subsidiaries. Fortress Biotech focuses on accelerating the timeline from early-stage development to regulatory approval and commercialization by leveraging in-house expertise in clinical operations, regulatory affairs, manufacturing and business development.

The company’s business model centers on partnering with innovators to in-license or acquire promising assets, then delegating them to specialized subsidiary companies for focused development. These subsidiaries benefit from shared resources at Fortress Biotech, including project management, finance and legal support. This integrated approach allows each affiliate to pursue programs in therapeutic areas such as oncology, rare diseases, inflammation and infectious diseases, while maintaining operational agility and scientific rigor.

Fortress Biotech’s pipeline encompasses small molecules, biologics and gene therapies in various stages of clinical and preclinical evaluation. Key programs include novel immuno-oncology agents, enzyme replacement therapies for rare genetic disorders and advanced gene-editing candidates. The company conducts research and development activities primarily in the United States, with certain programs benefiting from international collaborations and strategic partnerships to expand global reach and access to specialized manufacturing facilities.

Founded in 2006 by Dr. Lindsay A. Rosenwald, Fortress Biotech has grown through a series of strategic acquisitions and financings aimed at strengthening its product portfolio. The company’s leadership team brings together experienced executives and scientific advisors with backgrounds in drug development, regulatory strategy and commercialization. Fortress Biotech continues to pursue opportunities that align with its mission of delivering innovative therapies to patients with high unmet medical needs.

Key Stats

• Today's Range: $7.00 to $7.14
• 50-Day Range: $6.87 to $9.47
• 52-Week Range: $4.72 to $9.49
• Volume: 15,914 shs
• Average Volume: 11,963 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: 32.82%
• Price Target: N/A
• Consensus Rating: N/A

FBIOP Stock Analysis - Frequently Asked Questions

How have FBIOP shares performed this year?

Fortress Biotech's stock was trading at $6.65 at the start of the year. Since then, FBIOP shares have increased by 7.2% and is now trading at $7.13.

How do I buy shares of Fortress Biotech?

Shares of FBIOP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 8/09/2025
• Next Earnings (Estimated): 8/11/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FBIOP
• CIK: 1429260
• Web: www.fortressbiotech.com
• Phone: 781-652-4500
• Fax: N/A
• Employees: 170
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $57.78 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A